Items Tagged ‘myeloproliferative neoplasms’

April 14th, 2015

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these […]

View full entry

Tags: blood cancer, hydrea, hydroxyurea, improvement, jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


March 25th, 2015

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression

By

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib, CTI BioPharma Corp and Baxter International Inc, announced these findings from a Phase III clinical trial called PERSIST-1. Myelofibrosis is a type […]

View full entry

Tags: blood cancer, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, pacritinib, PERSIST-1, research


December 16th, 2014

Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera

By

CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Polycythemia vera is a slow-growing type of blood cancer […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


December 15th, 2014

Switching from Best Available Therapy to Jakafi® Improves Outcomes in Polycythemia Vera

By

Patients with polycythemia vera (PV) who begin treatment with best available therapy and then switch to treatment with Jakafi® (ruxolitinib) experience improved outcomes. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Polycythemia vera is a slow-growing type of blood cancer that belongs […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


December 11th, 2014

Jakafi® Appears Effective in the Treatment of Essential Thrombocythemia

By

By interfering with protein signaling linked to blood cell production, Jakafi® (ruxolitinib) may be effective in the treatment of essential thrombocythemia (ET) in patients who progress on or can’t tolerate Hydrea® (hydroxyurea). These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Essential thrombocythemia […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


September 30th, 2014

Myeloproliferative Neoplasms: When Good Cells Go Bad

By

The word has taken on a meaning that extends beyond the medical definition. Cancer is deadly; it is dangerous; it means bad news. But when we hear the words, “You have cancer,” what do we really need to know about what is happening in the body? A general definition of cancer is probably familiar to […]

View full entry

Tags: mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News


June 18th, 2014

Have a Question about Myeloproliferative Neoplasms? Join us on July 23rd

By

CancerConnect announces the opportunity to engage with a myeloproliferative neoplasm (MPN) expert, on July 23rd, 2014. In this Ask the Expert Series, questions will be answered about polycythemia vera, essential thrombocythemia and myelofibrosis in the MPN Community on CancerConnect. CancerConnect is a safe and private online support community for cancer patients and caregivers. Join the […]

View full entry

Tags: essential thrombocythemia, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycytehmia vera